text:
Sea Witch Rising Blog Tour: Review, Playlist, Giveaway
"The Little Mermaid" takes a twisted turn in this thrilling sequel to villainess origin story Sea Witch, as the forces of land and sea clash in an epic battle for freedom, redemption, and true love.
Runa will not let her twin sister die. Alia traded her voice to the Sea Witch for a shot at happiness with a prince who doesn't love her. And his rejection will literally kill her—unless Runa intervenes.
Under the sea, Evie craves her own freedom—but liberation from her role as Sea Witch will require an exchange she may not be willing to make. With their hearts' desires at odds, what will Runa and Evie be willing to sacrifice to save their worlds?
Told from alternating perspectives, this epic fairy tale retelling is a romantic and heart-wrenching story about the complications of sisterhood, the uncompromising nature of magic, and the cost of redemption.
Sea Witch Rising (Sea Witch #2)
by Sarah Henning
Release Date: August 6th 2019
Genre: Fantasy, Young Adult, Retellings
Book Links:
Goodreads: https://www.goodreads.com/book/show/42800505-sea-witch-rising
Amazon: http://tiny.cc/hmyo7y
iTunes https://books.apple.com/us/book/sea-witch-rising/id1441299835
B&N: https://www.barnesandnoble.com/w/sea-witch-rising-sarah-henning/1129708887?ean=9780062931474#/
Kobo: https://www.kobo.com/gb/en/ebook/sea-witch-rising-2
Google Books: https://books.google.co.uk/books/about/Sea_Witch_Rising.html?id=2SV2DwAAQBAJ&redir_esc=y
Bookdepository: https://www.bookdepository.com/Sea-Witch-Rising-Sarah-Henning/9780008356064?ref=grid-view&qid=1559513162298&sr=1-3
Sea Witch Rising by Sarah Henning is a reimagining of The Little Mermaid. This story follows Alia and Runa, twin mermaids and daughters of the Sea King. Alia is in love with a human. Not just any human. She is in love with Niklas the grandson of Niklas from book one. We already knew this was coming. She decides to make a trade with the Sea Witch. The Sea Witch gives her four days. Four days to prove that the human shows true love for her. If Alia is unable to prove this true love, then she will lose her voice for forever. Sounds familiar right? Runa doesn't understand why Alia would make this bargain. What is it about this human that is so important? Runa is concerned that her sister is throwing her life away for nothing.
Evie is trapped by the Sea King and she is desperate for her freedom. She struggles with her lack of power. Evie continues to make bad choices because she is struggling. As the reader we really get to discover who the Sea Witch is. How she became stuck and chained to her lair. We learn of all the pain and heartbreak she has gone through.
I found Alia to be a bit flat. She tended to be more annoying that interesting. I think her sister Runa really steals the show in this book. Runa show the reader what sisterly love looks like. She wants the very best for her sister and she wants her sister to be taken care of. Runa is really trying to find herself in this story. The Sea King is a greedy fool. He keeps his daughters close to him for their power and magic because he desires to have it all. He tends to be cruel and cold hearted. Who is the real Sea Witch in this story? He definitely had a much bigger part to play in this story than his counterpart in The Little Mermaid.
One of the things I really enjoyed in Sea Witch Rising was that Alia and Runa used sign language to communicate. They've known sign language since they were little so when Alia lost her voice, this was an easy way for them to communicate. I loved the use and creativity for this one.
This novel definitely served as a platform for some political issues as well. I felt like the push of politics was a little much for the story. I didn't feel like it added anything but it focused on greed, invasions and the invention of boats a lot. How humans are harming the ocean. At least that is how I took it. I don't think it is a bad thing to add your views into a novel, I just wish it flowed with the story better.
I think this retelling of the Hans Christian Anderson's The Little Mermaid is a good one. I like the new perspective. I am really enjoying the backstory to one of the most beloved villains out there. These books really show why we should sympathize with the Sea Witch and I love getting to know her back story. I am interested to see if Henning will expand anymore on this world and these characters.
Sea Witch Rising Playlist – Sarah Henning
https://music.apple.com/us/playlist/sea-witch-rising/pl.u-RRbVvxDCmad2Re
1. Blank Space – Taylor Swift
2. All Our Lives – Andrew McMahon in the Wilderness
3. Cecilia and the Satellite – Andrew McMahon in the Wilderness
4. Cold, Cold, Cold – Cage the Elephant
5. Trouble – Cage the Elephant
6. Lovefool – The Cardigans
7. Sit Still, Look Pretty – Daya
8. Ship To Wreck – Florence + The Machine
9. Let Me Go – Hailee Steinfeld & Alesso
10. Rivers and Roads – The Head and the Heart
11. All We Ever Knew – Signs of Light
12. I Keep Going to the River to Pray – Julie & The Dreggs
13. Praying – Kesha
14. Rise – Katy Perry
15. Can't Hold Us – Macklemore & Ryan Lewis
16. Crazy for You – Madonna
17. Like a Prayer – Madonna
18. The One Moment – OK Go
19. This Too Shall Pass – OK Go
20. We Belong – Pat Benatar
21. I Want You – Savage Garden
22. &Run – Sir Sly
23. You Need to Calm Down – Taylor Swift
24. We All Die Trying To Get it Right – Vance Joy
25. Fire and the Flood – Vance Joy
Sarah Henning is a recovering journalist who has worked for the Palm Beach Post, Kansas City Star and Associated Press, among others. While in South Florida, Sarah lived and worked through five hurricanes, which gave her an extreme respect for the ocean. When not writing, she runs ultramarathons, hits the playground with her two kids and hangs out with her husband Justin, who doubles as her long-suffering IT department. Sarah lives in Lawrence, Kansas, which, despite being extremely far from the beach, happens to be pretty cool.
Website: https://www.sarahhenningwrites.com/
Goodreads: https://www.goodreads.com/author/show/14671253.Sarah_Henning
Twitter: https://twitter.com/shhenning
Instagram: http://instagram.com/shhenning
Starts: 16th July 2019
Ends: 30th July 2019
Tour Schedule:
https://fantasticflyingbookclub.blogspot.com/2019/06/tour-schedule-sea-witch-rising-sea.html
The Unofficial Addiction Book Fan Club - Welcome Post
NovelKnight - Interview
The Reading Corner for All - Review + Favourite Quotes + Dream Cast
Jrsbookreviews - Review
Adventures Thru Wonderland - Review
Luchia Houghton Blog - Review + Favourite Quotes
The Reading Chemist - Review + Favourite Quotes
A Dream Within A Dream - Review
L.M. Durand - Review + Favourite Quotes
Moonlight Rendezvous - Review + Favourite Quotes
Library of a Book Witch - Review
Utopia State of Mind - Review + Favourite Quotes
Dazzled by Books - Review + Playlist
Confessions of a YA Reader - Guest Post
Here's to Happy Endings - Review
The Book Nut - Review + Playlist
Morgan Vega - Review + Favourite Quotes + Playlist
July 21st
Kait Plus Books - Interview
Frayed Books - Review
Bookish_Kali - Review + Favourite Quotes
Bookishly Nerdy - Review + Favourite Quotes
The Reading Life - Guest Post
Amy's Booket List - Review
The Desert Bibliophile - Review
Book Rambler - Review
Postado por Ali Kiki �s July 19, 2019
Marcadores: fantastic flying book club fantastic flying book tour giveaway playlist review Sea Witch Sea Witch Rising the little mermaid


text:
Looking for current products? Click here
A/V Processor (4)
A/V Receiver (6)
Audio Processor (1)
Blu-Ray Player (1)
Projector (4)
AVM Series (7)
BLX Series (1)
D2v Series (1)
Integrated Series (1)
LTX Series (4)
MRX Series (6)
TLP Series (1)
BLX Series
BLX 200
Fast load time, 1080p upscaling with 1080p24 compatibility, BD Live, Dolby TrueHD, DTS-HD Master...
LTX Series
LTX 300v
LTX 300
TLP Series
TLP 1
A state-of-the-art A/V preamplifier/processor/tuner complete with the award-winning Anthem Room Correction (ARC) system.
Fully featured 7.1-channel A/V processor boasts eight HDMI inputs and 2 parallel HDMI outputs, Dolby TrueHD, DTS-HD Master Audio, PCM 24/192, highest quality 1080p upscaling with premium quality A/D and D/A converters. 3D equipped.
Advanced 7.1-channel A/V processor with Anthem Room Correction (ARC).
The Audio Video Master … a power performer. The most affordable high-end multizone controller on the market puts the full A/V experience in your hands!
The same award-winning platform as its more expensive sibling, the D2v. 7-channel A/V processor with 8 HDMI inputs and 2 parallel HDMI outputs, Dolby TrueHD, DTS-HD Master Audio, PCM 24/192, highest quality 1080p upscaling, 1080p24 compatibility. Includes Anthem Room Correction (ARC) and 3D capability.
AVM 50v
7.1-channel A/V processor with Anthem Room Correction (ARC).
AVM 50
AVM 50 is a cutting-edge home theater audio/video processor with HDMI switching and video...
AVM 40 is a cutting-edge home theater audio processor / pre-amp with HDMI switching and video...
The AVM 30 is a cutting-edge home theater audio processor / pre-amp with video switching,...
AVM 20 v2
The AVM 20 is a state-of-the-art four path A/V Preamplifier / Surround Sound Processor, with...
The AVM 2 is a state-of-the-art three path, A/V Preamplifier / Surround Sound Processor with...
High-End Multichannel A/V Receivers with ARC 1M Anthem Room Correction
Choose 7 channels: 120 watts per channel; 7 channels: 100 watts per channel; or 5 channels: 80 watts per channel. IP and RS-232 control. 7 rear and one front-panel HDMI input, dual HDMI outputs. 4K upscaling and pass-through. Advanced Load Monitoring keeps an eye on output. Robust IP and RS-232 control. Remote control apps for iOS (Apple) and Android.
7-channel A/V receiver with Anthem Room Correction (ARC). 120 watts per channel continuous power...
7-channel A/V receiver with Anthem Room Correction (ARC 1M). 120 watts per channel continuous power...
7-channel A/V receiver with Anthem Room Correction (ARC 1M); 100 watts per channel continuous power...
7-channel A/V receiver with Anthem Room Correction (ARC); 100 watts per channel continuous power...
5-channel A/V receiver with Anthem Room Correction (ARC 1M); 80 watts per channel continuous power...
5-channel A/V receiver with Anthem Room Correction (ARC); 80 watts per channel continuous power into...
$999 each USD
Integrated Series
High-End 2-Channel Stereo Integrated Amplifier,
delivering 225 watts of continuous power per channel.
Music lovers, two-channel enthusiasts, vinyl aficionados looking for a phono input for your record player, this one's for you. All-in-one 2-channel analog solution offers the performance of high-end separates without the higher cost and complexity.
Stereo power amplifier; 225 watts per channel continuous power into 8 ohms.

redpajama_set_name: RedPajamaCommonCrawl


text:
McClintock and Strong Biblical Cyclopedia
Frontlet
(only in the plur. טוֹטָפֹת totaphoth', prob. fillets, from an obsolete root טוּŠto bind about [Gesenius, Thes. Heb. page 548]; Sept. ἀσαλευτά [v.r. ἀσαλευτόν, apparently pointing טוֹטֶפֶת], i.e.m immovable; Vulg. vaguely appensum quid, movebuntur, and collocate) occurs only in three passages (Ex 13:16; De 6:8; De 11:18), and each time in the form of a proverbial similitude, "as frontlets between your eyes," and also coupled with another similar expression, "as a sign (or token) upon your hand" (comp. Ex 13:9; "as a memorial between your eyes"), in connection with a command to observe the Mosaic law. In Exodus the expression is used more immediately with reference to the ordinance respecting the consecration of the first-born and the Passover solemnity; but in the two passages of Deuteronomy it relates to the precepts and statutes of the old covenant generally. The meaning in charging the Israelites to "bind them for a sign upon their hand, and have them as frontlets between their eyes," evidently is, that they should keep them as distinctly in view, and as carefully attend to them, as if they had them legibly written on a tablet between their eyes, and bound in open characters upon their hands; so that, wherever they looked, and wbatever they did, they could not fail to have the statutes of the Lord before them. That no actual written memorial was intended to be enjoined upon the Israelites is clear from the nature of the case, since no writing to be worn either between the eyes or upon the hand could by possibility have served the purpose of legibly expressing all the statutes and ordinances of the law. It is clear, also, from the alternative phrases witg which those in question are associated such as, "That the Lord's law may be in thy mouth" (Ex 13:9); "That these words shall be in thine heart;" "That ye shall lay up these my words in your heart and in your soul" (De 6:6; De 11:18), as well as from the parallel sayings of a later day (Pr 6:21; comp.
3:3; 4:21). But the Jews, some time after their return from Babylon (it is not known exactly when), gave the direction about having the precepts of the law as frontlets a literal turn, and had portions of it written out and worn as badges upon their person. These are called by the modern Jews tephillin', תּפַילַּין (a word signifying prayers, but not found in the Bible; Buxtorf, Lez. Talm. col. 1743). These were strips of parchment, on which were written four passages of Scripture (Ex 13:2-17; De 6:4-9,13-22) in an ink prepared for the purpose. They were then rolled up in a case of black calfskin, which was attached to a stiffer piece of leather, having a thong one finger broad, and one and a half cubits long. Those worn on the forehead were written on four strips of parchment (which might not be of any hide except cow's hide — Nork, Bramm. und Rabb. page 211; comp. Hesych. s.v. Σκυτικὴ ἐπικουρία), and put into four little cells within a square case, on which the letter שׁ was written; the three points of the שׁ being "an emblem of the heavenly Fathers, Jehovah our Lord Jehovah" (Zohar, fol. 54, col. 2). The square had two thongs (רצַיעוֹה), on which Hebrew letters were inscribed; these were passed round the head, and after making a knot in the shape of ר, passed over the breast. This was called "the tephillah on the head," and was worn in the center of the forehead (Leo of Modena, Ceremonies of the Jews, 1:11, n. 4; Calmet, s.v. Phylactery; Otho, Lex. Rabbis. page 656). The Karaites, on the contrary, explained De 6:8; Ex 13:9, etc., as a figurative command to remember the law (Reland, Ant. page 132), as in similar passages (Pr 3:3; Pr 6:21; Pr 7:3; Song 8:6, etc.), and appealing to the fact that in Ex 13:9 the word is not טוֹטָפוֹת, but זַכָּרוֹן "a memorial" (Gerhardus on De 6:8; Edzardus on Berachoth. 1:209; Heidanus, De Orig. Erroris, 8, B. 6; Schbttgen, Hor. Hebr. 1:199; Rosenmuller, ad loc.; Hengstenberg, Pent. 1:458). Considering, too, the nature of the passages inscribed on the phylacteries (by no means the most important is the Pentateuch for the fathers are mistaken in saying that the Decalogue was used in this way, Jeremiah 1.c.; Chrysost. 1.c.; Theophyl. ad Matthew 23:5), and the fact that we have no trace whatever of their use before the exile (during which time the Jews probably learnt the practice of wearing them from the Babylonians), they were justified in claiming that the object of the precepts (De 6:8; Ex 12:9) was to impress on the minds of the people the necessity of remembering the law. But the figurative language in which this duty was urged supon the Jews was mistaken by the Talmusdists for a literal command. An additional argument against the literal interpretation of the direction is the dangerous abuse to which it was immediately liable. Indeed, such an observance would defeat the supposed intention of it, by substituting an outward ceremony for an inward remembrance. Accordingly, these badges were turned into instruments of religious vanity and display, and abused for selfish purposes by those who sought, by a great profession of legal ritualism, to hide their deficiency of inward principle. They even came eventually to be employed as charms or amulets, having a divine virtue in them to preserve the wearer from sin or from demoniacal agency; hence such sayings as these concerning them in the Talmudical writings: "Whosoever has tephilim upon his head ... is fortified against sin;" They are a bandage for cutting off," i.e., from various kimeds of danger or hostility (Spencer, 4, c. 5). Jerome (on Mt 23:5) speaks of them generally as worn by the Jews for guardianship and safety (ob custodiam et munimentum); "not considering that they were to be borne in the heart, not and the body." SEE PHYLACTERY.
⇒Bible concordance for FRONTLETS.
On the analogous practice alluded to in Re 13:16; Re 14:1, SEE FOREHEAD.
⇒Definition of frontlet
⇒See also the International Standard Bible Encyclopedia.
← Frontier
Fronton Le Duc, or Fronto Ducaeus →
Alphabetical Index Home and Information A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Don't trust your Bible study to a mere web search.
Better Bible Study With
SwordSearcher Bible Software
Discover the power of SwordSearcher: A complete Bible study package, with thousands of topical and encyclopedic entries all linked to verses, designed for meaningful Bible study.
3 Reasons to use SwordSearcher (Video)
Topical Outlines Nave's Bible Topics International Standard Bible Encyclopedia Online King James Bible King James Dictionary
The Cyclopedia of Biblical, Theological, and Ecclesiastical Literature. James Strong and John McClintock; Haper and Brothers; NY; 1880.
Website HTML, editorial descriptions, and images ©2020 StudyLamp Software LLC.
Source: McClintock and Strong Cyclopedia book module from SwordSearcher.
Verse reference tagging and popups powered by VerseClick™.


text:
Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
Beat Müllhaupt, Philip Bruggmann, Florian Bihl, Sarah Blach, Daniel Lavanchy, Homie Razavi, Sarah Robbins Scott, David Semela, Francesco Negro
Catalyzed by the concerns over the growing public health and economic burden of Hepatitis C virus (HCV) in Switzerland, a diverse group of experts and patient representatives came together in 2014 to develop the Swiss Hepatitis Strategy, setting targets for the elimination of viral hepatitis in Switzerland by 2030. Previous studies have reported the estimated number of chronic HCV infections and forecasted burden of disease given different intervention strategies. However, given new prevalence data by the Swiss Federal Office of Public Health, which decreased total infections by about half, an updated analysis is warranted. We aimed to provide an updated viremic prevalence estimate for Switzerland and evaluate the impact on forecasted liver related morbidity and mortality of an 'inaction' scenario and intervention scenarios to achieve the Global Health Sector Strategy for Viral Hepatitis and Swiss Hepatitis Strategy goals by 2030. A Markov disease-progression model was used to calculate the present and future burden of HCV infection by disease stage according to these different strategies. In 2017, there were an estimated 36,800 (95% UI: 26,900–39,200) viremic infections in Switzerland. Given the current standard of care, total viremic infections are expected to decline by 45%, while cases of decompensated cirrhosis, hepatocellular carcinoma, and liver-related deaths will decrease by 20%. If treatment and diagnosis efforts were to cease in 2018, late stage HCV-related morbidity and mortality would increase by 90–100% by 2030. Increasing treatment and diagnosis to achieve the Global Health Sector Strategy or Swiss Hepatitis Strategy goals by 2030, will reduce the number of chronic infections to less than 13,000 and 4,000, respectively. Although the HCV epidemic is declining in Switzerland, efforts to expand diagnosis and treatment are needed to achieve elimination by 2030.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0209374
Posted by HCV New Drugs at Monday, December 31, 2018 No comments:
File Under Is HCV elimination possible by 2030
The $35 billion race to cure a silent killer that affects 30 million Americans
Sun, December 30, 2018 7:39 AM
In the U.S. 30 million Americans suffer from a form of fatty liver disease that turns into a form of liver cirrhosis that leads to death unless a patient can receive a liver transplant. Now drug companies are spending billions to help find a cure.
Lori Ioannou
The race is on in the pharmaceutical industry to develop drugs to treat a form of fatty liver disease called nonalcoholic steatohepatitis, also known as NASH.
Industry experts estimate the global market for these new drugs is $35 billion.
The U.S. is spending $5 billion annually in health-care costs related to the disease, which include chemotherapy, transplants, tests and hospitalizations, reports the Center for Disease Analysis.
The National Institutes of Health estimates as many as 12 percent of U.S. adults have this disease, or 30 million people.
Read More: https://www.cnbc.com/2018/12/21/the-35-billion-race-for-a-cure-for-a-liver-disease-that-affects-millions.html
File Under Fatty Liver, NASH
Posted by HCV New Drugs at Tuesday, December 25, 2018 No comments:
Patients at New Jersey surgery center possibly exposed to HIV, hepatitis
More than 3,000 patients at New Jersey surgery center possibly exposed to HIV, hepatitis
The patients may have been exposed to blood-borne illnesses due to "lapses in infection control in sterilization," according to the surgery center.
By Kalhan Rosenblatt
An ambulatory surgery center in New Jersey may have exposed thousands of patients to HIV and hepatitis due to "lapses in infection control" and sterilization, the state's department of health said Monday.
More than 3,700 patients who had procedures at HealthPlus Surgery Center in Saddle Brook, New Jersey, may have been exposed to blood-borne illnesses such as HIV, hepatitis B, and hepatitis C, according to a statement from the center.
https://www.nbcnews.com/news/us-news/more-3-000-patients-new-jersey-surgery-center-possibly-exposed-n951791
File Under Transmission clinical setting
Symposium - New HCV Clinical Advances
Hepatitis Elimination
Sit back and watch a live symposium from the November 2018 Liver Meeting featuring table discussions with leading physicians discussing viral hepatitis, launched by Chronic Liver Disease Foundation (CLDF) on December 13, 2018.
Webcast may take a moment to load
1. Welcome and Introduction
Jordan Feld, MD, MPH
2. Breaking News: New HCV Clinical Advances
3. What Will it Take to Achieve Global Hepatitis Elimination by 2030: Lessons from Country Experiences
Nick Walsh, MD, PhD
4. Enhancing Access to HCV Testing and Treatment in Prisons: Lessons from the Australian Model
Alex Thompson, MBBS (Hons), PhD, FRACP
5. Recruiting and Training PCPs in Rural California-One County at a Time
Norah Terrault, MD, MPH
6. The Role of Civil Society in Hepatitis Elimination: WHA Campaign from the Primary Care & Patient Advocate Perspective
Su Wang, MD, MPH, FACP
7. Panel Discussion and Q&A
Posted by HCV New Drugs at Saturday, December 22, 2018 No comments:
File Under AASLD 2018 The Liver Meeting®, AASLD 2018 The Liver Meeting® video, HCV-Education
HCV Next Is Saying Goodbye
I was overcome with great sadness this morning after reading HCV Next, a monthly publication available online at Healio, has published their last issue.
Thank You Healio
Thank you to all those amazing people who made HCV NEXT possible each month. I am so grateful for every outstanding interview, expert analysis, news article and in-depth editorial that was published over the last five years. Please know each issue made a difference in the lives of hepatitis C patients struggling to reach the finish line.
Your publication will be missed!
Read the November/December Issue.
Healio HCV News
Please continue to keep up on your HCV news via our other news outlets: Healio Gastroenterology and Liver Disease, Infectious Disease News and, launching soon, Healio Primary Care.
Hepatitis C - Barriers To Eradication
Despite all of the advances in hepatitis C treatment, it remains a "silent epidemic" with more than 70 million people infected worldwide. In this months issue of HCV Next, Michael S. Saag, MD., writes about HCV eradication and the huge barriers standing in the way; Passing the Torch from Implementation to Eradication.
Today, two different groups of people are at risk for hepatitis C; baby boomers, that is people born between 1945 and 1965 and young people - or - people who inject drugs. Although, HCV screening strategies for baby boomers have improved, the same is not true for people who use drugs, as reported by the good people at Imagine Hope recently over at NPR;
"Health care facilities that serve people who use drugs are well-positioned to initiate screening, studies show that often doesn't happen."
CEO of the American Liver Foundation added;
"It's a disease that can be cured the moment we identify somebody," says Tom Nealon, "Not testing is incomprehensible when you look at what hepatitis C does to their bodies and their livers."
Read the article: Why Aren't More Users Of Opioids Or Meth Screened For Hepatitis C?
NEW @ JAMA
During 2013 to 2016, what proportion of adults were living with hepatitis C virus (HCV) infection in each US state?
Regions with long-standing HCV epidemics, and those with newly emergent ones partly driven by the opioid crisis, face substantial HCV prevalence.
Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016
Prevalence of HCV infection varies widely in the United States. Highest rates are frequently in states deeply affected by the opioid crisis or with a history of increased levels of injection drug use and chronic HCV infection, particularly in the West. Progress toward hepatitis C elimination is theoretically possible with the right investments in prevention, diagnosis, and cure. The urgency for action and the resources necessary will vary by jurisdiction.
JAMA In The News: Hepatitis C Cases Cluster in States Hit Hard by Opioids
FRIDAY, Dec. 21, 2018 (HealthDay News) -- More than half of Americans with hepatitis C are living in just nine U.S. states -- five of those in a region hit hard by the opioid epidemic, a new study shows.
Medscape: Hep C and Drug Abuse Often Go Hand in Hand, but Screening Lags
Recent studies have shown that health care facilities often fail to screen people who use drugs. Not testing these patients for hepatitis C is an enormous missed opportunity, public health experts agree.
Young People with Hepatitis C Face Cirrhosis at Younger Age
One-third (32%) of people who contract hepatitis C virus (HCV) as a child will go on to develop cirrhosis at a median of 33 years post-infection, according to new research.
File Under HCV Awareness-screening strategies, HCV next, HCV-Education, opioid addiction, svr
'Alarming': Projected Burden of Liver Cancer in the US
Controlling the Global Burden of Liver Cancer
By Meg Barbor, MPH
According to Dr. Mohamed, target populations for hepatocellular carcinoma surveillance should include all patients with cirrhosis, regardless of etiology; patients with chronic HBV, particularly Asian men older than age 40 and women older than age 50; individuals with a family history of hepatocellular carcinoma; African and North American black individuals older than age 20 with HBV; and patients with noncirrhotic HCV and bridging fibrosis.
Read more: http://www.ascopost.com/issues/december-25-2018/controlling-the-global-burden-of-liver-cancer/
Roxanne Nelson, RN, BSN
@Medscape
The incidence of hepatocellular carcinoma in the US has been rapidly rising, but experts are cautiously optimistic that the trend can be reversed.
Over the past two decades, the incidence of hepatocellular carcinoma (HCC) has been steadily rising and is now a leading cause of cancer-related death in the United States. However, HCC disproportionally affects all US racial/ethnic minority populations, with blacks, Hispanics, and Asians experiencing higher age-specific incidence rates than non-Hispanic whites, according to an editorial in Journal of the National Cancer Institute (JNCI).
While incidence rates for HCC among most racial/ ethnic groups have steadily increased overall, the rates for blacks and Hispanics are projected to be the highest by 2030.
That said, even though the "projected burden of HCC in the United States is alarming, this future is not inevitable," write authors Amit G. Singal, MD and Caitlin C. Murphy, PhD, both of the University of Texas Southwestern Medical Center in Dallas.
They point to two studies recently published in the JNCI, which reviewed the racial/ethnic differences in incidence and projected future HCC burden. These two papers "paint a roadmap to reduce the increasing incidence and disparities in HCC in the United States," the editorialists comment.
Read the full article: https://www.medscape.com/viewarticle/906912
File Under liver cancer
Real-world effectiveness and safety of Harvoni with/without ribavirin hepatitis C virus genotype 1
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
Chen-Hua Liu, Chun-Jen Liu, Tung-Hung Su, Hung-Chih Yang, Chun-Ming Hong, Tai-Chung Tseng, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao
Published: December 21, 2018 https://doi.org/10.1371/journal.pone.0209299
Full-Text Article
The real-world data for the effectiveness and safety of sofosbuvir/ledipasvir (SOF/LDV) with or without ribavirin (RBV) in patients with hepatitis C virus genotype 1 (HCV-1) infection remain limited in Taiwan.
A total of 273 chronic HCV-1 patients receiving 8, 12, or 24 weeks of SOF/LDV with or without RBV were enrolled. The sustained virologic response rate at week 12 off-therapy (SVR12) by evaluable population (EP) and per-protocol population (PP) were assessed for effectiveness. The treatment discontinuation rate due to adverse events (AEs) and serious AE rate were assessed for safety. Baseline patient characteristics and on-treatment HCV viral kinetics associated with SVR12 were analyzed.
The SVR12 rates by EP and PP analyses were 96.7% (95% confidence interval [CI]: 93.9%-98.3%) and 97.5% (95% CI: 94.8%-98.8%), respectively. The rates of treatment discontinuation due to AE and serious AE were 0.4% and 4.4%, respectively. Seven patients with true virologic failure were relapsers. In 2 patients who were lost-to follow-up, one expired at treatment week 3 due to pneumonia which was considered not related to treatment, and one declined follow-up at off-therapy week 4. The SVR12 rates were comparable in terms of baseline patient characteristics and viral decline at week 4 of treatment.
SOF/LDV with or without RBV for 8–24 weeks is well tolerated and achieves a high SVR12 rate in patients with HCV-1 infection in Taiwan.
View Online: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0209299
File Under geno1, Harvoni® (Ledipasvir/Sofosbuvir), svr
Hepatitis C - Impact of treatment with direct-acting antivirals on anxiety and depression
Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C
Marta Gallach , Mercedes Vergara, Joao Pedro da Costa, Mireia Miquel, Meritxell Casas, Jordi Sanchez-Delgado, Blai Dalmau, Núria Rudi, Isabel Parra, Teresa Monllor, Meritxell Sanchez-Lloansí, Angelina Dosal, Oliver Valero, Xavier Calvet
Background and aim
Treatment of hepatitis C with direct-acting antiviral agents (DAA) has few side effects. Although pivotal studies suggested that DAA were safe in patients with psychiatric diseases who could not be treated with previous antiviral therapies, their effects on anxiety and depression have not yet been analysed in clinical practice. The aim of our study was to analyse anxiety and depression in the setting of DAA treatment in a clinical practice series.
All patients starting DAA treatment between November 1, 2014 and October 31, 2015 were eligible. Patients completed the Hospital Anxiety and Depression scale at different times during treatment. The results were plotted on line graphs and evaluated using a linear regression model with repeated measures.
One hundred and forty-five patients were included (11% with major psychiatric disorders; 32% on psychiatric treatment). Sustained virologic response (SVR) was achieved in 97.3% of cases. Anxiety and depression measures did not differ between time points. No differences between patients on psychiatric treatment or with advanced fibrosis or cirrhosis were found at any time point analysed.
DAA treatment had no impact on anxiety or depression during or after chronic hepatitis C infection treatment, even in high-risk patients with major psychiatric disorders.
Read More: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0208112
File Under Brain, Depression, HCV neurocognitive function, Other Conditions Related To HCV, side effects, side effects-direct-acting antivirals, svr
HCV patients treated with DAA undergo a marked reduction of insulin resistance
Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents
Alessandro Gualerzi, Mattia Bellan , Carlo Smirne, Margherita Tran Minh, Cristina Rigamonti, Michela Emma Burlone, Ramona Bonometti, Sara Bianco, Azzurra Re, Serena Favretto, Giorgio Bellomo, Rosalba Minisini, Gian Piero Carnevale Schianca, Mario Pirisi
The increased incidence of type 2 diabetes mellitus among hepatitis C virus (HCV) infected patients is likely due to viral-induced insulin resistance (IR). Indeed, control of diabetes in these patients benefits of successful antiviral treatment; whether the same applies to subtler alterations of glucose metabolism is unknown. We aimed to fill this gap.
The study population included 82 HCV-RNA positive patients (48 males, median age 66 years, 73 with advanced fibrosis, 41 HCV-1b), attending the liver clinic of an academic hospital to receive direct antivirals. None was previously known to be diabetic. All underwent a standard oral glucose tolerance test (OGTT) before antiviral treatment and right after its conclusion.
At baseline, the majority of patients had evidence of abnormal glucose metabolism (N. = 45, 55%; impaired fasting glucose 10%, impaired glucose tolerance16%, both the above 12%, 17% diabetes), while only 37 (45%) were normally glucose tolerant (NGT). At the end of treatment, HCV-RNA quantification was below the detection threshold (HCV-RNA <12 UI/ml), for all patients enrolled. A significant decrease in glucose and insulin plasma concentrations was observed, leading to a significant reduction in Homeostasis Model Assessment (HOMA)-IR (from 3.42 [2.66–5.38] to 2.80 [1.78–3.95];p<0.001) and a corresponding increase in insulin sensitivity (ISI Belfiore from 0.49 [0.26–0.75] to 0.64 [0.42–0.91];p<0.001), despite a significant reduction in insulin secretion (EFP Stumvoll from 1363 [959–1730] to 1264 [976–1588];p = 0.027). Importantly, HOMA-IR reduction occurred also in the subgroup of NGT patients (p = 0.017). The number of NGT patients increased to 53, 65% (p = 0.013) paralleled by a reduced number of those satisfying criteria for prediabetic conditions (31 (38%) vs. 17 (21%); p = 0.025).
Glucose metabolism parameters of HCV infected patients improve early after antiviral treatment, with benefits that are not limited to diabetics. These findings confirm how deep and widespread is the impairment of insulin pathways exerted by HCV infection.
File Under diabetes, diabetes-insulin resistance, Other Conditions Related To HCV
December Newsletters: Curing Hep C May Dial Back Liver Damage
Hi folks, over the next few weeks I'll be taking a holiday break to spend time with the family. Can't wait to start my Christmas shopping, trick out my tree, and bake some millennial sugar cookies. Using Pillsbury ready to make slice-and-bake cookies, add sprinkles after baking. Bad Nana!
In any event, here's your list of December newsletters with blog updates from across the web.
News & Review
Catch up on what you missed this week by reading one of two HCV week in review publications:
The Weekly Bull is published by the Canadian non-profit organization HepCBC, the second publication by Caring Ambassadors Program, is filled with news as well, in addition to a monthly review of relevant HCV research published on PubMed.
CDC: Could be a tough flu season based on early viruses, hospitalizations
By Anne-Gerard Flynn
The country could be in for another challenging flu season. There are already 11 pediatric deaths associated with the flu and hospitals rates among very young children are high, according to the Centers for Disease Control and Prevention.
NPR - Even in a setting with an identified risk factor in opioid-use disorder, too few youths are being screened for hepatitis C
As the number of people who inject drugs and share needles has soared, the rate of infection with Hep C has climbed too. Yet many drug treatment patients aren't tested for the liver-damaging virus.
Great news for New Zealanders pangenotypic regimen Maviret unrestricted access from Feb 2019 with $0 co-payment - PHARMAC funding decision gives Kiwis with hepatitis C access to a potential cure
December Newsletters
The aim of infohep.org is to develop a high-quality online resource to increase awareness of viral hepatitis, its treatment, and the needs of people living with viral hepatitis in Europe.
The December edition of the infohep bulletin is now online:
http://www.infohep.org/page/3409947
Global trends in non-alcoholic fatty liver disease
NAFLD can occur in lean people too
Hepatitis C and the US opioid epidemic
Resistance testing for hepatitis C
Rwanda aims for hepatitis C elimination
Egypt hepatitis C elimination
Hep is an award-winning print and online brand for people living with and affected by viral hepatitis. Offering unparalleled editorial excellence since 2010, Hep and HepMag.com are the go-to source for educational and social support for people living with hepatitis.
Winter Issue 2018
Curing Hep C May Dial Back Liver Damage
Hep C Testing Slowly Rising Among Baby Boomers
People Who Inject Drugs Succeed With Hep C Treatment
The HCV Advocate newsletter is a valuable resource designed to provide the hepatitis C community with monthly updates on events, clinical research, and education.
In this month's newsletter coverage of the Liver Meeting continues; read easy to understand commentary on HCV-related topics that matter most to patients. In next month's issue notable research on liver cancer presented at the meeting will be featured as well.
After The Liver Meeting Summary: Viral Hepatitis & Fatty Liver Disease
For patients - An index of links provide an overview of the meeting with a focus on HCV; read expert analysis of key data, interviews with leading researchers and clinicians, or listen to live presentations, view slidesets and capsule summaries. Sit back and watch daily clips or a live symposium, finally review a webinar with all the notable Liver Meeting updates.
HCV Action brings together hepatitis C health professionals from across the patient pathway with the pharmaceutical industry and patient representatives to share expertise and good practice.
Read the latest: HCV Action e-update
The World Hepatitis Alliance goal is to achieve a world free from viral hepatitis, World Hepatitis Alliance provides global leadership in awareness-raising, advocacy and in efforts to find the missing millions.
The New York City Hepatitis C Task Force is a city-wide network of service providers and advocates concerned with hepatitis C and related issues. The groups come together to learn, share information and resources, network, and identify hepatitis C related needs in the community. Committees form to
work on projects in order to meet needs identified by the community.
December Newsletter: Reminder: NYC Hep C Task Force Meeting. December 5 (3-5 PM) @ 132 West 32nd St.
NYC Hep C Task Force
All - Hep Free NYC Newsletters
Hepatitis NSW provides information, support, referral and advocacy for people affected by viral hepatitis in NSW. We also provide workforce development and education services both to prevent the transmission of viral hepatitis and to improve services for those affected by it.
GI & Hepatology News covers the world of liver disease with breaking news, on-site medical meeting coverage, and expert perspectives both in print and online.
View all updates here....
Hepatitis Victoria is the peak not-for-profit community organisation working across the state for people affected by or at risk of viral hepatitis.
View the Latest Newsletter, or relax and listen to a short podcasts interviewing health experts and practioners on topics related to viral hepatitis - have a listen!
The British Liver Trust is the leading UK liver disease charity for adults – we provide information and support; increase awareness of how liver disease can be prevented and promote early diagnosis; fund and champion research and campaign for better services.
View Recent Newsletters, here.
The Hepatitis C Trust is run by patients with the goal of eliminating HCV in the United Kingdom. The Trust's mission is to reverse the rapidly increasing death toll caused by hepatitis C in the UK until no-one dies from this preventable and treatable disease and, ultimately, it is all but eradicated in this country.
The National Viral Hepatitis Roundtable (NVHR) is national coalition working together to eliminate hepatitis B and C in the United States.
NVHR 2018 Year in Review
View all NVHR newsletters
Check out the latest National Institutes of Health Newsletter.
Plan Your Plate - Shifting to a Healthy Eating Style
I Help C
Karen Hoyt is devoted to offering support and accurate information to people coping with the effects of hepatitis C.
Latest blog entry: Holiday and Health Problems
Find Karen on Facebook
Lucinda K. Porter
Lucinda Porter is a nurse, speaker, advocate and patient devoted to increasing awareness about hepatitis C.
View all new blog updates, here....
Hep is an award-winning print and online brand for people living with and affected by viral hepatitis.
Latest blog updates:
Hepatitis: Bad News, Good News
By Lucinda K. Porter, RN
10 Steps to Living One Day at a Time
By Connie M. Welch
Hepatitis C Cure
By Greg Jefferys
View all blog updates, here...
AGA Blog
Gastroenterology and Clinical Gastroenterology and Hepatology
Latest blog entry by Dr. Kristine Novak: What Are the Effects of Virologic Response to Treatment on Outcomes of Patients With Chronic HBV Infection and Decompensated Cirrhosis?
Life Beyond Hepatitis C
Life Beyond Hep C is where faith, medical resources and patient support meet, helping Hep C patients and their families navigate through the entire journey of Hep C.
Latest blog entry: 5 Common Questions and Answers about Hepatitis C Treatment
View all updates, here...
Canadian Liver Foundation
We strive to improve prevention and the quality of life of those living with liver disease by advocating for better screening, access to treatment, and patient care.
Latest blog entry: Tips for a struggling caregiver
Hepatitis B Foundation
The Hepatitis B Foundation is a national nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide.
Latest blog entry: My partner has been diagnosed with hepatitis B. Can transmission be prevented by vaccination?
Ask An Expert: Managing Hepatitis Delta During Pregnancy
View all updates, here....
ADRLF (Al D. Rodriguez Liver Foundation)
Al D. Rodriguez Liver Foundation is a non-profit organization that provides resources, education and information related to screening, the prevention of and treatment for the Hepatitis Virus and Liver Cancer.
Alzheimer's and Liver Health: What's the Connection?
At HepatitisC.net we empower patients and caregivers to take control of Hepatitis C by providing a platform to learn, educate, and connect with peers and healthcare professionals.
Part 1: Doctors and Dragons: The Adventure Continues - By Rick Nash
Here We Go Again: Dealing with Chronic Illnesses - By Daryl Luster
KevinMD
Kevin Pho is a practicing physician and most known for his blog KevinMD. Thousands of authors contribute to his blog: primary care doctors, surgeons, specialist physicians, nurses, medical students, policy experts. And of course, patients, who need the medical profession to hear their voices.
View latest blog entry, here...
Harvard Health Blog
The goal of our publications is to bring people around the world the most current health information that is authoritative, trustworthy, and accessible, drawing on the expertise of the 10,000+ faculty physicians at Harvard Medical School.
Latest blog entry: Alcohol use disorder: When is drinking a problem?
Benefits of a healthy diet — with or without weight loss
Safe and effective use of insulin requires proper storage
University of Michigan - Lab Blog
Providing physicians with virtual access to specialists can be lifesaving to liver disease patients.
View all updates: Lab Blog
New HCV Clinical Advances
JAMA Patient Page
This JAMA Patient Page describes recent advancements in hepatitis C treatment.
Treating Hepatitis C
From a medical point of view, almost all patients with hepatitis C should be treated.
Posted by HCV New Drugs at Wednesday, December 19, 2018 No comments:
File Under AASLD 2018 The Liver Meeting®, hbv, Liver Fibrosis, newsletters, opioid addiction, svr
Progress and difficulties in the elimination of HCV infection: A population-based cohort study in Spain
Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain
Regina Juanbeltz, Alejandra Pérez-García, Aitziber Aguinaga, Iván Martínez-Baz, Itziar Casado, Cristina Burgui, Silvia Goñi-Esarte, Jesús Repáraz, José Manuel Zozaya, Ramón San Miguel, Carmen Ezpeleta, Jesús Castilla
Full-text article available online: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0208554
The World Health Organization set targets to eliminate hepatitis C virus (HCV) infection through detection and treatment of all cases by 2030. This study aimed to describe the progress and difficulties in the elimination of HCV infection in Navarra, Spain.
Using electronic healthcare databases, we performed a population-based prospective cohort study to describe changes in the prevalence of diagnosed active HCV infection at the beginning of 2015 and the end of 2017, the rate of new diagnoses and the rate of post-treatment viral clearance (PTVC) during this period.
At the beginning of 2015 there were 1503 patients diagnosed with positive HCV-RNA, 2.4 per 1000 inhabitants, and at the end of 2017 the prevalence had decreased by 47%. In the study period, 333 (18 per 100,000 person-years) new positive HCV-RNA cases were detected, but only 76 (23%; 4.2 per 100,000 person-years) did not have anti-HCV antibodies previously detected. Prevalent cases and new diagnoses of active infection were more frequent in men, people born in 1950–1979, HIV-infected patients and in those with lower income levels. Among patients with HCV-RNA, 984 achieved PTVC (22.7 per 100 person-years). PTVC was less frequent in patients born before 1940, in immigrants and in patients with lower income levels.
The prevalence of diagnosed active HCV infection has dropped by almost half over three years, because the number of patients with PTVC was much higher than the number of new diagnoses. Interventions specifically targeted at population groups with less favourable trends may be necessary.
Efforts to Eliminate Hepatitis C
File Under Efforts to Eliminate Hepatitis C, HCV Worldwide
More Raw Beef Recalled After Nationwide Salmonella Outbreak
Amy Held
More than 2,500 tons of raw beef are being added to a recall in connection with a salmonella outbreak that federal officials say has sickened hundreds of people across 25 states.
The Arizona-based JBS Tolleson processing plant initially recalled about 3,500 tons of potentially contaminated beef in October. JBS, the top global meatpacker that owns the plant, still maintains the move ensured all of the affected product had already been removed from store shelves
https://www.npr.org/2018/12/05/673702290/more-raw-beef-recalled-after-nationwide-salmonella-outbreak?utm_source=dlvr.it&utm_medium=twitter
File Under FDA, recall
New Test Could Detect All Types of Cancer in Just Minutes
This New Test Could Detect All Types of Cancer in Just Minutes
ABU SINA, LAURA G CARRASCOSA & MATT TRAU, THE CONVERSATION
Researchers have developed a test that could be used to diagnose all cancers. It is based on a unique DNA signature that appears to be common across cancer types.
The test has yet to be conducted on humans, and clinical trials are needed before we know for sure if it can be used in the clinic.
Each cancer type, whether it be breast or bowel cancer, has different genetic and other features. A test that detects one cancer may not work on another.
Researchers have long been looking for a commonality among cancers to develop a diagnostic tool that could apply across all types.
Our research, published in the journal Nature Communications, has found that cancer DNA forms a unique structure when placed in water. The structure is the same in DNA from samples of breast, prostate and bowel cancers, as well as lymphoma.
We used this discovery to develop a test that can identify the cancerous DNA in less than ten minutes.
How our test works
Current detection of cancer requires a tissue biopsy – a surgical procedure to collect tissue from the patient's tumour. Researchers have been looking for a less invasive diagnostic test that can detect cancers at an earlier stage.
One possibility, still in development, is a liquid biopsy, testing for circulating cancer DNA in the blood.
Our test also uses circulating cancer DNA but involves a different detection method.
Nearly every cell in a person's body has the same DNA, but studies have found that cancer's progression causes this DNA to undergo considerable reprogramming.
This change is particularly evident in the distribution pattern of a tiny molecule called a methyl group, which decorates the DNA.
A normal cell DNA's distinct methyl pattern is crucial to regulating its machinery and maintaining its functions. It is also responsible for turning genes on and off. Altering this pattern is one of the ways cancer cells regulate their own proliferation.
This methyl patterning has been studied before. However, its effect in a solution (such as water) has never been explored.
Using transmission electron microscopy (a high-resolution microscope), we saw that cancerous DNA fragments folded into three-dimensional structures in water. These were different to what we saw with normal tissue DNA in the water.
In the lab, gold particles are commonly used to help detect biological molecules (such as DNA). This is because gold can affect molecular behaviour in a way that causes visible colour changes.
We discovered that cancerous DNA has a strong affinity towards gold, which means it strongly binds to the gold particles.
This finding directed us to develop a test that can detect cancerous DNA in blood and tissue. This requires a tiny amount of purified DNA to be mixed with some drops of gold particle solution.
By simply observing the colour change, it is possible to identify the cancerous DNA with the naked eye within five minutes.
The test also works for electrochemical detection – when the DNA is attached onto flat gold electrodes.
Since cancer DNA has higher affinity to gold, it provides a higher relative electrochemical current signal in comparison to normal DNA. This electrochemical method is highly sensitive and could also eventually be used as a diagnostic tool.
For this test to work properly the DNA must be pure. So far we have tested more than 200 tissue and blood samples, with 90 percent accuracy. Accuracy is important to ensure there are fewer false positives – wrongly detecting cancer when there is none.
The types of cancers we tested included breast, prostate, bowel and lymphoma. We have not yet tested other cancers, but because the methylation pattern is similar across all cancers it is likely the DNA will respond in the same way.
It is a promising start, though further analysis with more samples is needed to prove its clinical use.
The next step is to do a large clinical study to understand how early a cancer can be detected based on this novel DNA signature. We are assessing the possibility to detect different cancer types from different body fluids from early to later stages of cancer.
We are also considering whether the test could help monitor treatment responses based on the abundance of DNA signatures in body fluid during treatment.
Abu Sina, Research Fellow, The University of Queensland; Laura G. Carrascosa, Postdoctoral Research Fellow, The University of Queensland, and Matt Trau, Professor, The University of Queensland.
File Under cancer, Other Health News
Appeal lodged against decision to uphold Gilead's patent on hepatitis C drug
Video - The story of sofosbuvir illustrates how research and development for new prescription drugs really works: When Big Pharma plays for keeps, who wins and who loses?
Paris – Six organisations, including Médecins Sans Frontières (MSF), have just appealed the European Patent Office's September decision to uphold US pharmaceutical corporation Gilead Science's patent on the key hepatitis C drug sofosbuvir.
The appeal – filed by Médecins du Monde (MdM), MSF, AIDES (France), Access to Medicines Ireland, Praksis (Greece) and Salud por Derecho (Spain) – states that the European Patent Office (EPO) should revoke Gilead's patent because it does not meet the requirements to be a patentable invention from a legal or scientific perspective.
The appeal comes exactly five years after sofosbuvir was first approved for use, in the US, where Gilead launched the drug at US$1,000 per pill, or $84,000 for a 12-week treatment course.
The corporation has made more than $58 billion from sales of the drug and its combinations in the last five years.
In March 2017, civil society organisations from 17 European countries filed a challenge against Gilead's patent on the base compound of sofosbuvir, stating that Gilead's patent claims were not legitimate, primarily because they lack inventiveness.
Out-of-control drug prices
Gilead's monopoly on sofosbuvir in Europe has allowed the corporation to charge excessive prices for the drug.
In some European countries, Gilead charges as much as €43,000 for a 12-week treatment course, when generic versions of the same course can be purchased for less than €75 outside Europe.
"What is the point of medical innovation if people and health systems cannot afford the products coming out of it? Gaëlle Krikorian, head of policy at MSF's Access Campaign"
These exorbitant prices have forced health systems to ration sofosbuvir, leaving thousands of people in Europe with hepatitis C without treatment.
Despite compelling arguments presented by the organisations opposing the patent, on 14 September 2018 the European Patent Office (EPO) decided to uphold Gilead's patent, thereby making it impossible to produce or sell affordable generic versions of the drug in Europe.
"The EPO is being too lenient with pharmaceutical corporations, giving them a free pass," said Olivier Maguet of MdM's drug pricing campaign. "There needs to be much greater scrutiny in Europe when it comes to determining whether pharmaceutical corporations deserve patents or not; otherwise, unmerited monopolies will continue to result in out-of-control drug prices."
The appeal aims to put an end to pharmaceutical corporations' abuse of medicines patenting systems to increase their own profits – including in countries outside Europe, where patent offices often follow the EPO's decisions when they decide whether to grant a patent to a pharmaceutical corporation or not.
As some new patented drugs – such as those to treat cancer – come to market with price tags reaching €400,000 per person, there is an urgent need to reform patent systems so that people have access to the medicines they need to stay alive and healthy.
"Unmerited patents in Europe are giving pharmaceutical corporations the monopoly power that allows them to charge exorbitant prices for many lifesaving drugs," said Gaëlle Krikorian, head of policy at MSF's Access Campaign.
The excessive prices Gilead is charging for sofosbuvir have kept this breakthrough medicine away from millions of people with hepatitis C in Europe and around the world. What is the point of medical innovation if people and health systems cannot afford the products coming out of it?"
https://www.msf.org/appeal-lodged-against-decision-uphold-gileads-patent-hepatitis-c-drug
Link to a collection of current articles regarding the effectiveness and safety of generic hepatitis C medicines, as well as addressing the high cost, insurance restrictions; private insurers/Medicaid and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"
File Under Sofosbuvir/Cost
China's National Medical Products Administration Approves Harvoni®
China's National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6
--Harvoni Offers Highly Effective, Short-Duration, Pan-Genotypic Treatment for Chinese Patients with HCV Infection--
--Harvoni Achieved Cure Rate (SVR12) of 100 Percent in Clinical Trial of Chinese Patients with Genotype 1--
FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 4, 2018-- Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the National Medical Products Administration (NMPA) has approved Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) in China for the treatment of chronic hepatitis C virus (HCV) genotype 1-6 infection in adults and adolescents aged 12 to 18 years.
Hepatitis C is a significant public health challenge. Nearly 10 million people in China are estimated to have chronic HCV, with approximately 58 percent having HCV genotype 1 infection.
"The multicenter clinical trials in China have shown that the once-daily single tablet treatment regimen of Harvoni achieved a 100% SVR12 (defined as undetectable HCV RNA 12 weeks after completing therapy) rate in treatment patients with genotype 1 HCV infection," said Professor Lai Wei, Peking University People's Hospital and Institute of Hepatology, Beijing.
"Gilead has continued to develop and deliver new treatments for HCV to help enable people with HCV the potential to be cured," said John McHutchison, AO, MD, Chief Scientific Officer, Head of Research and Development, Gilead Sciences. "We are pleased to offer an important new treatment option that can help patients achieve HCV cure and further support efforts to stem the epidemic in China."
The approval of Harvoni in China is supported by an open-label, Phase 3b study, which was conducted at 18 study centers in mainland China between May 2016 and July 2017. The study evaluated 12 weeks of treatment with Harvoni in 206 genotype 1 HCV patients, including treatment-naïve and treatment-experienced patients without cirrhosis or with compensated cirrhosis.
https://www.gilead.com/news/press-releases/2018/12/chinas-national-medical-products-administration-approves-harvoni-ledipasvirsofosbuvir-for-treatment-of-chronic-hepatitis-c-virus-genotype-16
File Under genotypes;All, Harvoni® (Ledipasvir/Sofosbuvir)
Millions flock to free tests as Egypt seeks to eradicate hepatitis C
Mahmoud Mourad, Lena Masri
MIT NAMA (Reuters) - When Houaida Mabrouk heard about a government campaign that offers free hepatitis C screenings, she hesitated, afraid of testing positive. But after many from her community started visiting health clinics to get checked, she changed her mind.
"I thought, 'I should go too'," Mabrouk said, speaking at a clinic in the Mit Nama village near Cairo before learning she did not have the virus.
Egypt, which has the highest rate of hepatitis C in the world, is carrying out an unprecedented campaign to detect and treat the disease in a bid to eliminate it by 2022. It aims to test the entire adult population — about 50 million people.
https://www.reuters.com/article/us-health-egypt-hepatitis-c/millions-flock-to-free-tests-as-egypt-seeks-to-eradicate-hepatitis-c-idUSKBN1O21IO
File Under HCV Awareness-screening strategies, HCV Worldwide-Egypt
After The Liver Meeting 2018 Summary: Viral Hepatitis & Fatty Liver Disease
The Liver Meeting® 2018
San Francisco, CA.
Page updated: December 13, 2018
After The Liver Meeting
Hi folks, today we have a nice summary of the Liver Meeting, highlighting significant research on both viral hepatitis and fatty liver disease. Follow each post-meeting link provided below and start reviewing expert analysis of key data presented at the meeting, listen to audio live from the meeting, or view slidesets, and capsule summaries.
HCV Advocate December Newsletter
In this month's HCV Advocate Newsletter coverage of the Liver Meeting continues; read easy to understand commentary on HCV-related topics that matter most to patients. In next month's issue notable research on liver cancer presented at the meeting will be featured.
http://hcvadvocate.org/news/NewsUpdates_pdf/Advocate_2018/advocate1218.pdf
The Liver Meeting® Content Now Available On Demand
Open Access: The Best of The Liver Meeting®. This product, bundled as downloadable slide sets, contains highlights from the meeting and investigates nine topics with key findings, data and analyses.
View the summary slide decks by topic.
Alcoholic Liver Disease
Basic and Translational Research
Cholestatic and Autoimmune Liver Diseases
Liver and Biliary Cancer
NAFLD/NASH
Pediatric Liver Diseases
Portal Hypertension/Cirrhosis
"Liver Meeting 2018 Updates" presented by Tatyana Kushner, MD, MSCE from Mount Sinai Medical Center, available now over at HepCure.
Chronic Liver Disease Foundation
Symposium live from the meeting featuring table discussions with leading physicians discussing viral hepatitis, launched in December by CLDF. The primary goal of this CME symposium is to better understand how to effectively identify, manage, and treat patients with viral hepatitis in order to achieve viral eradication by 2030.
Website Healio - Twitter @HealioHep
Liver transplantation highlights from The Liver Meeting 2018
This year at The Liver Meeting, data presented on liver transplantation focused on comorbid complications, such as alcohol misuse and obesity, and their correlated…
ID Practitioner
Hepatitis C debrief: Therapy has matured, access issues remain
The Liver Meeting 2018: Hepatitis B novel therapies debrief – key abstracts
HCV Expert Interview with Jordan Feld, MD, MPH
In this interview, Jordan Feld, MD, MPH, discusses key highlights from studies presented at The Liver Meeting 2018, held recently in San Francisco by the American Association for the Study of Liver Diseases (AASLD).
Website: Hep
The Liver Meeting 2018 Roundup
By Benjamin Ryan
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
infohep
Website infohep Twitter - @infohep
This month's infohep bulletin focuses on news from The Liver Meeting 2018, organised by the American Association for the Study of Liver Diseases (AASLD), which took place in San Francisco, USA, from 9 to 13 November 2018.
Link: Conference bulletin
Website Medscape Twitter @Medscape
Viral Hepatitis: Five Highlights From the Liver Meeting
Dr William Balistreri reports on the most important viral hepatitis news from this year's Liver Meeting.
Clinical Care Options
Website Clinical Care Options - Twitter @CCO_Hepatitis
Hot Topics in NASH
Audio: NAFLD/NASH Studies Influencing My Practice Following San Francisco 2018
Audio: Key Viral Hepatitis Studies Influencing My Practice Following San Francisco 2018
Slides: Clinical Impact of New Viral Hepatitis Data From San Francisco 2018
CCO Coverage: https://www.clinicaloptions.com/hepatitis/conference-coverage/san-francisco-2018
Healio presents highlights of Fatty Liver and NASH data presented this year at The Liver Meeting.
Fatty liver highlights from The Liver Meeting 2018
Hep B Foundation
After the Liver Meeting, Dr. Tim Block, the @HepBFoundation's co-founder & President, answered some of the most asked questions about the path to a hepatitis B cure. This is a two-part series. Read the first Q & A here: http://ow.ly/UEAT50jOb61
Quick Review: Each Day Of The Meeting
Practice Point is once again launching daily clinical clips reviewing hot topics in HCV, presented each day at the meeting. Although the activity is intended for physicians and health care professionals, anyone, especially patients can benefit from each 5-minute review as well:
Independent Conference Coverage from the 2018 Annual Meeting of the American Association for the Study of Liver Disease (AASLD)*
In this video series, Dr. Saab will present 'what you need to know in 5‐minutes' regarding today's presentations from AASLD 2018 in San Francisco, CA
Free "registration" is required, once accomplished:
ACCESS ACTIVITY
Answer 3 question pre-test, and click Access Activity.
Twitter - @Practice_Point
Navigate This Blog - Stay Updated
Easy to navigate index; link to meeting coverage, updates during and after the meeting, with a focus on viral hepatitis, nonalcoholic steatohepatitis/NASH, liver cancer and liver transplantation.
Check back for updates
Enjoy the weekend!
File Under AASLD 2018 The Liver Meeting®, AASLD 2018 The Liver Meeting® Summary, Fatty Liver, hbv, newsletters, svr
Swiss Hepatitis Strategy: Is HCV elimination possi...
The $35 billion race to cure a silent killer that ...
Patients at New Jersey surgery center possibly exp...
'Alarming': Projected Burden of Liver Cancer in th...
Real-world effectiveness and safety of Harvoni wit...
Hepatitis C - Impact of treatment with direct-acti...
HCV patients treated with DAA undergo a marked red...
December Newsletters: Curing Hep C May Dial Back L...
Progress and difficulties in the elimination of HC...
More Raw Beef Recalled After Nationwide Salmonella...
New Test Could Detect All Types of Cancer in Just ...
Appeal lodged against decision to uphold Gilead's ...
China's National Medical Products Administration A...
Millions flock to free tests as Egypt seeks to era...
After The Liver Meeting 2018 Summary: Viral Hepati...


Two sites in Berlin and Konstanz. More than 450 smart heads actively involved. More than 125 years of tradition in pharmaceutical production. A leading role in the areas of women's health and hemorrhoidal complaints in Germany. International activities in the growing markets of Asia and Eastern Europe: that is DR. KADE.
As an independent family company, DR. KADE has been successful in the pharmaceutical sector since 1886. By concentrating on the business segments of gynecology, proctology, and pain treatment, we consciously focus on our long-term core competencies and are one of the key actors – both for prescription drugs and self-medication (over-the-counter). DR. KADE is one of the leading providers in the women's health sector in Germany (for hormonal therapy during menopause and gynecological antimycotics) and for the treatment of hemorrhoidal complaints. With innovative products DR. KADE is also a competent partner for doctors and patients in pain therapy – e.g. for treating back pain.
Through joint ventures and sales cooperation we are not only active in our core market Germany, but also in other European and non-European countries, for example in Poland (Kadefarm) and Japan (Maruho).
Our staff is the basis of our success: More than 400 employees at both German sites ensure that we are right at the forefront of a highly dynamic market environment. We also maintain a close relationship with doctors and pharmacists. We offer comprehensive information and advice, qualified training, and reliable service. Our joint goal is to improve the quality of the life of patients.


text:
Q: Copying a file to the clipboard guys! Does anybody know how to achieve this? I mean: if I want to put a string to the clipboard I do
NSPasteboard *pboard = [NSPasteboard generalPasteboard];
[pboard declareTypes:[NSArray arrayWithObject:NSPasteboardTypeString] owner:self];
[pboard setString:@"aString" forType:NSPasteboardTypeString];

but what if I want to put a file into the clipboard? I'd like to find a way to use a filepath as a parameter and then being able to paste that file wherever I want in the Finder, via contextual menu or CMD-V.
Can anybody help me?
Thanks a lot!

A: After HOURS AND HOURS AND HOURS of searching around, I finally got a short answer...
NSArray *fileList = [NSArray arrayWithObjects:filePath1, filePath2, nil];
NSPasteboard *pboard = [NSPasteboard generalPasteboard];
[pboard declareTypes:[NSArray arrayWithObject:NSFilenamesPboardType] owner:nil];
[pboard setPropertyList:fileList forType:NSFilenamesPboardType];

A: Put this together quickly, but is tested using both CMD+V and Contextual Paste.
NSURL *object = [[NSURL alloc] initFileURLWithPath:@"/Users/username/Desktop/main.png"];
NSPasteboard *pb = [NSPasteboard generalPasteboard];
[pb clearContents];

NSArray *objectsToCopy = [[NSArray alloc] initWithObjects:object, nil];
BOOL pasted = [pb writeObjects:objectsToCopy];

if(pasted) // paste was successful
    NSLog(@"pasted");

[object release];
[objectsToCopy release];
[pb release];

A: I haven't tried this but as I understand the documentation, all you have to do (at least in OS X 10.6+) is this:
NSURL *fileURL = [NSURL fileURLWithString:...];
NSPasteboard *pasteboard = [NSPasteboard generalPasteboard];
[pasteboard writeObjects:[NSArray arrayWithObject:fileURL]];

And to read the URL from the pasteboard:
NSArray *urls = [pasteboard readObjectsForClasses:[NSArray arrayWithObject[NSURL class]]
                                          options:[NSDictionary dictionaryWithObject:[NSNumber numberWithBool:YES] forKey:NSPasteboardURLReadingFileURLsOnlyKey]];
if ([urls count] == 1) {
    NSURL *myFileURL = [urls objectAtIndex:0];
    ...
}

redpajama_set_name: RedPajamaStackExchange


text:
How the Bailout Is Like a Hedge Fund.
It's massively leveraged. It's buying distressed assets. It's taking equity stakes …
Read more about Wall Street's ongoing crisis.
The Wall Street bailout is alive again. In an effort to make the $700 billion bailout palatable, the architects of the law have larded it up with all sorts of goodies, such as increasing the levels of deposit insurance, sparing some taxpayers the ravages of the Alternative Minimum Tax, and extending tax breaks for alternative energy. Henry Paulson's three-page sprig has sprouted into a 451-page Christmas tree. (The current version of the bill, in all its lengthy glory, can be seen here.)
What's most interesting about the Emergency Economic Stabilization Act of 2008 is just how much it reads like a prospectus for a hedge fund. In the past, hedge funds—secretive pools of capital—were open only to qualified (read: rich) investors. But with the stroke of a pen, President Bush will soon make all American citizens investors in the world's biggest fund—and a democratic one at that. Taxpayers won't just be the investors. We'll own the management company, too. Best of all? For at least a few months, we'll have the former CEO of Goldman Sachs run our investment for a very small fee. Call it the "Universal Hedge Fund."
Hedge funds use leverage: That is, they borrow money to amplify their returns. The Universal Hedge Fund will use massive leverage, borrowing up to $750 billion, which it will use to buy up distressed assets. The Universal Fund might best be described as a multi-multistrategy fund. Its stated goals are to maximize returns to its investors while promoting general market stability and bolstering the crippled housing market.
The fund's bylaws give the manager (the treasury secretary) significant discretion. He can buy troubled mortgage-related instruments from finance companies (Section 3[9][a], Page 5). But he can also invest in "any other financial instrument that the Secretary, after consultation with the Chairman of the Board of Governors of the Federal Reserve System, determines the purchase of which is necessary to promote financial market stability" (Section 3[9]B, Page 6). The manager then has the authority to manage the assets as he sees fit (Section 106[B], Page 22), collecting revenue streams, holding bonds to maturity, or flipping them for a quick profit (Section 106[c], Page 22). Like many of today's sharpest hedge funds, the Universal Fund will also have the ability to drive a harder bargain by demanding equity stakes, or new debt securities, from the institutions it is helping (Section 113[d], Page 35). It can also do what many of the big hedge funds, and so-called "funds of funds," do: bring in outside managers to run the investment (101[C][3], Page 8).
There are some important differences between the Universal Fund and its private sector peers. Hedge funds thrive on secrecy. The Universal Fund will operate with maximum transparency, disclosing all new sales and purchases on the Web within two days (Section 114[A], Page 39). Rather than send in all our money upfront, we hedge-fund investors will give the manager $250 billion to start with (Section 115[A][1], Page 40). And the proceeds won't be distributed via dividends or end-of-year partnership distributions. Rather, revenues and profits "shall be paid into the general fund of the Treasury for reduction of the public debt" (Section 106[d], Page 22).
The Bush administration's desire to turn all Americans into participants in the capital markets through the privatization of Social Security never got off the ground. But in the last months of its second term, it has managed to pull off something of a coup. Soon enough, we'll all collectively own various securities issued by lots of big companies. Too bad the Ownership Society is happening only because we became a Bad Debt Society.


PROS: Confident, FUNNY, kind, smart, excellent singer who can read music and match pitch. She can wrestle crocodiles and dingos simultaneously and she always speaks her mind.
CONS: She's a bit PG 13 and base. At first she comes off as obnoxious, but as you get to know her she's a gem.
BEST SHINING MOMENT: Admitting that her real name is Fat Patricia, but she didn't like that so she changed it to Fat Amy. It wasn't that she didn't like her body image, she didn't like that people were making fun of her body image, so she turned the tables on them and changed her name.
WHY I CHOOSE Fat Amy: Fat Amy is a pretty upbeat person. She takes what life gives her and celebrates it. Thumbs up to Rebel Wilson for her no holds bar portrayal of Fat Amy in the film.
This entry was posted on Sunday, December 8th, 2013 at 10:56 pm	and tagged with Body image, Fat Amy, Humour, Pitch Perfect, Rebel Wilson and posted in Thought of the Day.	You can follow any responses to this entry through the RSS 2.0 feed.


Recently, Zoo staff have been visiting the uplands of Dartmoor at the crack of dawn - but why?
Our three wrinkled hornbill chicks have hatched and flown the nest.
2014 is the centenary of the start of the First World War, one of the most devastating conflicts in history.


text:
Home » The Roxy Letters (Compact Disc)
The Roxy Letters (Compact Disc)
By Mary Pauline Lowry, Jayme Mattler (Read by)
"Move over Bridget Jones, Roxy is here to stay! Thank goddess! I loved every sentence of The Roxy Letters; I found myself laughing out loud at some of her wacky antics. I also loved the quirky cast of characters that danced across the pages, and I think Roxy is the perfect antihero for the new millennium. I can't wait to see where Mary Pauline Lowry's career is headed!"
— Kathleen Caldwell, A Great Good Place for Books, Oakland, CA
Bridget Jones's Diary meets Where'd You Go, Bernadette in this comic novel about twenty-something Roxy, an unlucky-in-love Whole Foods employee, aspiring artist, and sometimes vegan, who teams up with her two best friends to save Austin from gentrification--and to save her personal life--in whatever way she can.The Roxy Letters is a hilarious and heartwarming novel told through the letters that the charming and hapless Roxy, a twenty-eight-year-old Austin native, sends to her ex-boyfriend (and current roommate) Everett. Roxy is underemployed, sexually frustrated, and uninspired. Tired of her job as a deli maid at the original Whole Foods, Roxy daydreams of breaking out of her funk and finding a job that will get her creative juices flowing. She also wouldn't mind finding love and finding herself off the brink of financial ruin--though Everett's late rent payments aren't helping her with the latter. On top of it all, gentrification is slowly changing her beloved Austin in new and evilly corporate ways. When a new Lululemon pops up at the intersection of 6th and Lamar where the old Waterloo Video used to be, Roxy can stay silent no longer. Encouraged by her ex-deli counter comrade Annie--now assistant to the Whole Foods CEO and planning an animal rights revolution from the inside--and her new friend Artemis, a vivacious and mercurial man-eater with a string of personas and paramours all over town, Roxy decides to take action. But can this spunky, unforgettable millennial keep Austin weird, avoid arrest, and discover good sex, true love, and her purpose in life in the process?
Publication Date: April 7th, 2020
Humorous - General
Kobo eBook (April 6th, 2020): $13.99
Paperback (April 6th, 2021): $17.00
Hardcover (April 7th, 2020): $26.00


text:
You are here: Home / Cookie Policy
Cookies and Other Information Tracking Technologies
Kivu Consulting, Inc.'s cookie policy and information regarding the purpose and management of cookies are outlined below. Also included is the use of other online services that Kivu Consulting, Inc. may use and how these services track user information. Website users are encouraged to review the full policy below to understand what information is collected by Kivu Consulting, Inc. and how that information is used by Kivu Consulting, Inc.
A "cookie" is a small data file placed on your browsing device by websites you have visited and stored on your browsing device. The information stored in a cookie is used for many purposes such as identifying a user, customizing a web application, or managing website performance. For more information about cookies and controlling cookies, visit http://www.aboutcookies.org/.
Why we use cookies?
Kivu Consulting, Inc.'s websites uses cookies, in conjunction with Kivu Consulting, Inc.'s web server log files, to provide a more personalized and responsive experience for users who visit Kivu Consulting, Inc.'s websites. Cookies assist Kivu Consulting, Inc. in understanding your visit to the website and how you use this site. Cookies also assist Kivu Consulting, Inc. in diagnosing and managing the performance of its websites.
By using this site, you agree that Kivu Consulting, Inc. can place cookies on your computer or device. As explained above, you can control and manage cookies in various ways. If you have configured your browser to disable cookies, you may still browse this website and download materials.
Types of Cookies Used
There are two types of cookies that Kivu Consulting, Inc. employs in relation to its website. The cookies fall into two categories that are described below.
Performance Cookies Performance cookies monitor the use of a website by collecting information to track unique victors, pages visited, time spent on specific pages, and other details regarding a website visit. Kivu Consulting, Inc. uses these cookies for the purpose of analyzing website performance, user experience and opportunities to improve the website. See specific information below regarding analytic services used by Kivu Consulting, Inc. and specific cookies.
Social Media Cookies In order to make the sharing of content easier, some website pages may contain content links, tools or applications that are linked to third party social media service providers such as LinkedIn. These social media service providers may set their own cookies on your browsing device when you visit their website or use their tools or applications. Kivu Consulting, Inc. does not control these cookies and you should check a specific social media service provider's website for further details about how they use cookies.
1. Google Analytics (and Map Generator)
This website uses Google Analytics cookies to track and analyze site visits. Google Analytics sets a cookie using a small amount of JavaScript code on web pages that are tracked in a website. The information generated by a Google Analytics' cookie (including IP address) will be transmitted to and stored by Google on servers in the United States. (Map Generator is a map tool provided by Google and Google Analytics tracks a website's referral to a Map Generator web page.)
_utma Determines first visit to the sitefrom a particular browser
_utmb Used to establish and continue a user session with the site
_utmc Holds timestamp of the exact moment in time when a visitor leaves the site
_ utmz Records the type of referral to reach the site including direct, referring link, email link, Web site search.
For more information, visit Google's help pages and privacy policy. For information specifically about Google Analytics cookies, refer to Google Analytics' cookie usage.
Google's Privacy Policy
2. StatCounter
This website uses StatCounter to track and analyze site visits. StatCounter uses cookies to analyze how website visitors use the site. The information generated by StatCounter's cookie (including IP address) will be transmitted to and stored by StatCounter in accordance with their privacy policy.
is_unique Used to determine first-time or returning visitor to a website and to estimate unique visits to that site.
For more information, visit StatCounter's privacy policy. For information specifically about StatCounter cookies, refer to StatCounter's cookie page.
StatCounter's Privacy Policy
How a User Can Manage Cookies Using a Browser?
There are a variety of tools available to users to control cookies and similar technologies. Cookie management includes limiting the types of cookies installed on a browsing device and deleting cookies. Examples of Internet browser cookie management can be reviewed for the following browsers:
Microsoft Internet Explorer: http://windows.microsoft.com/en-us/internet-explorer/delete-manage-cookies#ie=ie-10
MacIntosh Safari: http://support.apple.com/kb/index?page=search&fac=all&q=cookies%20safari
Mozilla Firefox:http://support.mozilla.org/en-US/kb/cookies-information-websites-store-on-your-computer
If you have configured your browser to disable cookies, you may still browse this website and download materials.
How a User Can Manage Performance (Analytics) Cookies?
A user can opt-out of having browsing activity tracked within websites recorded by analytics cookies. Visit the following sites to opt out of analytic services used on this website:
Kivu Consulting, Inc. may use the following social media service providers. For more information about the privacy policies (including cookies) of the social media service providers, please visit the following sites:
LinkedIn: http://www.linkedin.com/static?key=privacy_policy
Google+: http://www.google.com/policies/privacy/ and http://www.google.com/policies/technologies/cookies/
YouTube: http://www.youtube.com/static?gl=US&template=privacy_guidelines
Twitter: http://twitter.com/privacy
Kivu Consulting, Inc. may use Google AdWords for advertising on the Google website or through Google's advertising network. Kivu Consulting, Inc. does not use AdWords directly on its websites. For information on Google AdWord pirivacy and cookie policies, please refer to Google's website.
Kivu Consulting, Inc. uses MailChimp to communicate with select individuals. Communications include newsletters, announcements, and training opportunities. In each MailChimp communication, an option to unsubscribe is placed in the footer of the communication.
MailChimp uses a web beacon (or a tiny tracking .gif image) in emails to track emails that are opened. MailChimp also tracks email links that are clicked. To learn more about MailChimp and its information collection, handling and retention practices, review MailChimp's Privacy Policy. (A web beacon is a transparent pixel image that may be used in collecting information about website usage, e-mail response and tracking.)
Date of Last Revision: July 1, 2017


Expectant mothers in Southeastern North Carolina have the opportunity to experience prenatal care in a group setting that offers patient education augmented by group discussion and, ultimately, improved outcomes. NHRMC Physician Specialists - OB/GYN Specialists has adopted centering, a method that offers women group prenatal care in a comfortable setting.
OB/GYN Specialists implemented the program about four years ago at the suggestion of two nurse practitioners. It was certified by the Centering Healthcare Institute in October 2016.
During centering, expectant mothers with similar due dates are placed into groups of up to 10 that meet 10 times during their pregnancies.
The women receive handbooks that discuss each topic in detail, and they record their vital signs in the book. Once their vital signs have been taken, the women move behind a screen for private belly checks. They visit while others check in and then move into a circle of chairs to discuss the topic of the day.
Each session lasts one and a half to two hours. The residents and medical assistants lead the sessions, but the women are active participants. "We're letting them problem solve and share stories, and we guide the discussions," Jaworski said.
A recent session focused on preterm labor, and one of the moms actually went into preterm labor two days later. By knowing the signs and heading to the hospital, she was able to save her baby. She said if she hadn't understood it, she might not have gone to the hospital and there could have been a different outcome.
Aside from the better care, the women also gain extra support from the other members. Jaworski said, "They are developing a network of support that you simply don't get in traditional care. They make connections that last way beyond pregnancy." The groups often have reunions six to eight weeks after the last member has given birth. One group has continued to meet for playdates a year after giving birth.
Ultimately, women who participate in centering tend to see improved outcomes. "There are a lot of benefits proven over time, such as lower pre-term deliveries, lower c-section rates, higher breastfeeding initiation, higher rates of contraceptive use after delivery and higher show rates for postpartum visits," Stinson said.
The practice is hoping to add more groups and continue to expand the program. The providers are also looking forward to offering the program to Spanish-speaking women in the near future.
To learn more about centering at the Betty H. Cameron Women's & Children's Hospital, call 910.662.9300.


There are no coincidences in life, everything happens for a reason—every action from the past affects the future. When the stars are aligned and the magic is right, it causes sparks and results in something great. Thus, after accidentally meeting the Director of New York Film Academy, Dan Mackler, at a Russian TV-channel, the writer, producer and director, Costa Fam, began a new stage of his career.
Despite the desire to continue an education at NYFA, Costa Fam, due to family and business, couldn't leave everything and move to America. By a happy coincidence, the New York Film Academy was holding a 13-Week Producing Workshop in Moscow, taught by Lydia Cedrone, Paul Brown and Gilbert Shilton.
During this course, Fam began working on a global historical project called Witnesses. He was nurturing this idea since his visit to the Auschwitz Memorial and Museum where he was struck by a display of thousands of shoes of the concentration camps' victims.
A trilogy, Witnesses, is the first feature film from the former Soviet Union produced in memoriam of the Holocaust victims. Each part of the project provides a whole new unique way to look at the greatest catastrophe of the 20th century.
«Shoes», film tizer. from General & C on Vimeo.
Shoes (2012) is the opening short of the trilogy. It shows the story from the point of view of a pair of red shoes, which begins in a shop window and tragically ends in a mass grave at the Auschwitz concentration camp.
The film was also an official contender for Best Short Film at the 2013 Academy Awards. This is the first film to be granted permission from "Auschwitz-Birkenau" to shoot on the museum territory, making this exception for the art project. Also, this short was added to the movie collection of Yad Vashem (Israel), along with outstanding films about the Holocaust by Spielberg, Polanski, and Benigni.
The second part of a trilogy, Brutus, starring Oksana Fandera and Filipp Yankovskiy, tells the story of the Holocaust through the eyes of a German Shepherd named Brutus, who is separated from his beloved mistress. After being separated, he becomes a watchdog at a concentration camp. Brutus is trained and psychologically manipulated at the camp, which turns him from a harmless pet into a vicious killer. The film is based on the eponymous story written by famous Czech writer Ludvik Askenazy.
Brutus is currently in post-production and is scheduled to premiere in the summer of 2016.
The world of the third short in the trilogy, Violin, based on a short story, revolves entirely around the unique instrument that has passed through all the horrors of the war. The story begins in a violin shop in Nuremberg, where at the beginning of the 20th century the violin was created as a gift to a Jewish boy. The instrument changed many owners and appeared in various places. Its story ends a hundred years after its creation with a concert at the Wailing Wall of Jerusalem.
Costa Fam shared with NYFA that the lead character in the third and final part of the trilogy will be played by German actor Lenn Kudrjawizki (The Counterfeiters, Enemy at the Gates, The Transporter Refueled).
Lenn Kudrjawizki is a real treasure for Costa Fam. In addition to his amazing acting career, Lenn is a wonderful violinist who graduated from music conservatory.
Actors from previous parts of the trilogy will be involved as well, including Oksana Fandera, Vladimir Koshevoy and Mariya Zykova. Shooting will take place in Russia, Israel, Czech Republic, Poland and Belarus.
Costa, you have six children, how do you manage to achieve a balance between work and family?
On the one hand, it is impossible to achieve balance. On the other hand, I am absolutely happy in what I'm doing and I share this happiness with my children. In the end, it's not the amount of time spent together that affects relationships, but the quality. When I'm with my children, I try to find time for everyone. Often times, I try to be a friend rather than a parent. Also, each of my kids knows that he/she is "my favorite child" and that they can count on me to support them. I think that is the most important feeling for a child to feel about his dad.
What childhood dreams have you managed to bring to life?
Most of them: I do what I love. I also really wanted to travel – just in the last year I crossed the ocean over ten times. More interesting is what dreams I failed to realize. When I was a child I naively dreamed that all people on Earth can love one another, and there will be peace throughout the world. Now I understand that this is an impossible dream, but I can take small steps towards it and, by doing my job, build a ladder to the sky.
If you can call the past, what advice would you give your 20 year-old self?
I can't say that I regret anything in my life and would like to fix it, but one piece of advice I would give is to learn languages. Particularly English, in my case.
What advice would you give to our students, aspiring filmmakers?
Shoot, shoot and shoot! Unfortunately, in the filmmaking business we can't practice and rehearse like we could in sports and music. Fortunately, now you have an opportunity to shoot on camera or your phone and see the results instantly. Here is some practical advice: choose the scenes from your favorite films, invite aspiring actors (who also need training) and make your own remakes of those scenes. The results will surprise you a lot!


text:
Q: Scalable div larger than window Concept
I'm trying to get a list larger than the window, which will move depending on mouse position. The goal is to allow the user to see all list entries, whatever their amount.
Below is a simple image to illustrate the concept :

*

*Black frame is the window

*Black arrow is the mouse position

*Red line is the list

Problem
Currently, I can make this work only if I set the list width. I would like to not set this width.
Here's the code:

$(document).ready(function() {

    var widthPage = $('.strip').width();
    var widthStrip = $('.strip ul').width();

    $('.strip').on('mousemove', function(event) {
        var offset = $(this).offset();
        var relX = event.pageX - offset.left;
        var left = relX * (widthStrip - widthPage) / widthPage;
        $(this).find('ul').css('left', '-'+left+'px');
    });

});
/* Positioning */
.strip {
    position:relative;
    overflow: hidden;
}
.strip ul {
    position: absolute;
    top: 0; left: 0;
    width: 1750px;
}
.strip li {
    display: block;
    float: left;
}

/* Style */
body {
    padding: 0;
    margin: 0;
}
.strip {
    height: 30px;
    margin-top: 50px;
}
.strip ul {
    height: 30px;
    padding: 0;
    margin: 0;
}
.strip li {
    list-style: none;
    border: 1px solid #EBEBEB;
    margin-right: -1px;
    padding: 0 5px;
    line-height: 28px;
}

Lorem

Ipsum

Dolor

Sit

Amet

Consectetur

Adipisicing

Elit

Sed

Do

Eiusmod

Tempor

Incididunt

Ut

Labore

Et

Dolore

Magna

Aliqua

Ut

Enim

Ad

Minim

Veniam

Quis

Nostrud

Exercitation

Ullamco

Laboris

Nisi

Ut

Aliquip

Ex

Ea

Commodo

Consequat

A: The issue here is that to force the floated elements to expand beyond the page's width, you need to force their container to have a width sufficient to hold them all. I propose using display: inline-block instead, as they will continue so long as their container specifies white-space: nowrap.
.strip {
    position:relative;
    white-space: nowrap;
    overflow: hidden;
}
.strip ul {
    position: absolute;
    top: 0; left: 0;
    font-size: 0; /* prevent html whitespace from displaying */
}
.strip li {
    display: inline-block;
    font-size: 16px; /* reset font size so the elements appear */
}

After setting these styles, the list will scroll correctly without an explicit width set.

A: One way to do it would be to make .strip very large and change widthPage to a grandparent's width who's size is equivalent to the original parent's, in this case var widthPage = window.innerWidth;
Demo Here
Changed CSS
body { overflow-x: hidden; }
.strip {
    position:relative;
    overflow: hidden;
    width:10000px; /* Arbitrary large value */
}
.strip ul {
    position: absolute;
    top: 0; left: 0;
    width: auto;
}